KBC Group’s Trevi Therapeutics TRVI Stock Holding History

KBC Group’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$46K	Hold	2,464	–	–	﹤0.01%	1732
2026 Q1	$29K	Buy	+2,464	New	+$27.6K	﹤0.01%	1805

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

KBC Group's TRVI Position: Q2 2026 in Review

KBC Group held its Trevi Therapeutics (TRVI) position steady in Q2 2026 at 2,464 shares worth $46K. The position accounts for ﹤0.01% of the portfolio, ranked #1732.

KBC Group first reported a position in TRVI in Q1 2026 and has held it in 2 quarters since. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

KBC Group held 2,464 shares of Trevi Therapeutics worth $46K as of Q2 2026.
KBC Group left its Trevi Therapeutics share count unchanged in Q2 2026.
Trevi Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1732 holding.
KBC Group first reported a position in Trevi Therapeutics in Q1 2026 and has held it in 2 quarters since.
219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.